Bharat Biotech will partner with Spain’s Biofabri to develop, manufacture and distribute a novel, live attenuated tuberculosis vaccine candidate, the companies announced Wednesday. The tie-up aims to guarantee the future supply of MTBVAC in over 70 countries, “especially in Southeast Asia, and sub-Saharan Africa,” according to a joint press release.
The shot originated at the University of Zaragoza. Additional collaborators include the International AIDS Vaccine Initiative and the…
The International AIDS Vaccine Initiative and Spanish biopharma Biofabri announced on Wednesday that they will collaborate on Phase 3 efficacy studies for the novel tuberculosis vaccine candidate MTBVAC. The trials are scheduled to start in several African countries this year.
Biofabri licensed MTBVAC for commercialization from Spain’s University of Zaragoza.
The state of the hunt:
The U.S. FDA approved Gilead’s Veklury (remdesivir) for hospitalized Covid-19 patients 12 and older.
Vaccines
Phase 3 candidates:
J&J is “preparing to resume recruitment” for the…
The International AIDS Vaccine Initiative, in partnership with Spanish biopharma company Biofabri and the South African Tuberculosis Vaccine Initiative, announced this week that it will conduct a Phase 1b/2a trial to evaluate the novel tuberculosis vaccine candidate MTBVAC in an endemic population. Spain’s University of Zaragoza developed the candidate.